BOSTON—A trial evaluating multiple doses of aldafermin has found it effective and largely well tolerated in patients with compensated cirrhosis due to metabolic dysfunction–associated steatohepatitis.
In previous trials, the fibroblast growth factor 19 analog aldafermin (NGM Biopharmaceuticals) failed to meet its primary end point, but the latest multicenter, phase 2b, randomized, double-blind, placebo-controlled ALPINE trial, which correlated enhanced liver fibrosis (ELF) scores